Companies › Heronova Pharmaceuticals
3 active drug programs in 3 registered trials: 3 Phase 1; Oncology, Ophthalmology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| DC6001 | – | Phase 1 | Stargardt Disease | Dec 2026 |
| DC05F01 | – | Phase 1 | Solid Tumors | Dec 2027 |
| DC50292A MTAP inhibitor | MTAP | Phase 1 | Solid Tumor Malignancies | Jan 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07417566 | DC6001 | Phase 1 | Stargardt Disease | Ophthalmology | Dec 2026 |
| NCT06873555 | DC05F01 | Phase 1 | Solid Tumors | Oncology | Dec 2027 |
| NCT07071090 | DC50292A | Phase 1 | Solid Tumor Malignancies | Oncology | Jan 2028 |
Bristol-Myers Squibb Gilead Sciences BeOne Medicines CytosinLab Therapeutics Haisco Pharmaceutical Group Abbisko Therapeutics
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.